Pricing Log in Create free account
Saturday 17 October 2026 Export SIBN’s income statement to Excel — free account

SiBone

SIBN Healthcare Medical Devices

SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 15.2%, EPS grew 35.7%, free cash flow grew 60.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

19.68 0.23 −1.16%
Market cap
$892.3M
P/E
0.0×
Fwd P/E
−34.8×
Dividend yield
—
F-score
6/9
Altman Z
7.18
Beneish M
−3.08
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.66
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 10 3 4 5 1 2 5 1 2 8 1 2
Insider Ownership 4.31%

Capital & Financial Ratios $m

Market Cap 892.34
Revenue 213.60
Net Income (14.63)
Free Cash Flow (4.39)
Net Debt (110.31)
Current Ratio 9.15 (at or above 1.5: strong)
Debt/Equity 0.20 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (34.80) (negative: loss-making)
P/S ratio 4.10
P/B ratio 4.80
Past 5Y EPS Growth —
This Y EPS Growth 9.86%
Next Y EPS Growth 17.43% (at or above 15%: strong)
Next Y revenue growth 15.52% (at or above 10%: strong)
Next 5Y EPS Growth 26.24% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.6×, against a ten-year median of 4.8×; over the ten years it ranged from 1.2× in 2019 to 13.3× in 2021.
P/S against its own 10 years 29.15%
10-year low 10-year high
P/B against its own 10 years 54.23%
10-year low 10-year high
EV/Sales against its own 10 years 34.53%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 10.00
10.00
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 166 150 148 146
Receivables 22 27 30 31
Inventory 20 27 34 38
Other — — — —
211 208 216 220
2023 2024 2025 Q'26
Payables 5 6 5 9
ST’ Debt — — — —
Other — — — —
23 27 25 24

Compound Annual Growth %

10y 5y 3y
Sales — 22.32% 23.60%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.95% 21.78%

Revenue $m

Mar Jun Sep Dec Year
’26 53 56 — — —
’25 47 49 49 56 201
’24 38 40 40 49 167
’23 33 33 34 39 139
’22 22 26 26 32 106
’21 20 22 22 25 90
’20 17 14 20 22 73
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) 1 — — —
’25 (5) 0 2 2 (1)
’24 (8) (6) 0 1 (12)
’23 (11) (4) (2) (2) (19)
’22 (14) (15) (7) (7) (42)
’21 (9) (8) (9) (13) (40)
’20 (9) (8) (6) (8) (31)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (1) — — —
’25 (7) (2) (1) 0 (9)
’24 (10) (9) (3) (1) (23)
’23 (13) (6) (3) (3) (27)
’22 (16) (17) (10) (8) (51)
’21 (11) (10) (10) (14) (46)
’20 (10) (8) (6) (9) (33)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.10) (0.09) — — —
’25 (0.15) (0.14) (0.11) (0.04) (0.44)
’24 (0.27) (0.22) (0.16) (0.11) (0.75)
’23 (0.32) (0.30) (0.25) (0.27) (1.13)
’22 (0.52) (0.54) (0.41) (0.32) (1.79)
’21 (0.37) (0.42) (0.48) (0.43) (1.71)
’20 (0.47) (0.44) (0.33) (0.28) (1.50)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 16.27 14.08 7.20 18.48 11.14 12.44 11.70 12.50

Analyst estimates 2026–2028

Powerpack
High — — 21.96 23.03 32.00 37.21 23.71 29.51 21.64 21.07
People
People Employees — 168 183 262 295 352 357 344 349 376
Revenue/emp, $m 0.00 0.29 0.30 0.26 0.25 0.26 0.30 0.40 0.48 0.53
Income, $m
Income, $m Revenue 42 48 55 67 73 90 106 139 167 201
Gross margin, % 87.73 89.35 91.27 89.91 87.87 88.43 85.24 78.78 79.03 79.57
EBT (21) (23) (17) (38) (44) (57) (61) (43) (31) (19)
EBT margin, % (48.90) (48.01) (31.51) (57.06) (59.54) (62.75) (57.57) (31.20) (18.49) (9.41)
Net income (21) (23) (17) (38) (44) (57) (61) (43) (31) (19)
Depreciation 1 1 1 1 2 4 4 2 (1) 3
Per share, $
Per share, $ Revenue 12.70 13.84 6.97 2.72 2.53 2.72 3.11 3.61 4.03 4.68
Earnings (6.21) (6.65) (2.20) (1.55) (1.50) (1.71) (1.79) (1.13) (0.75) (0.44)
Cash flow (5.06) (5.06) (1.83) (1.28) (1.06) (1.19) (1.22) (0.49) (0.30) (0.02)
Capex (0.13) (0.14) (0.12) (0.10) (0.09) (0.19) (0.28) (0.20) (0.25) (0.20)
Free cash flow (5.19) (5.19) (1.94) (1.38) (1.14) (1.39) (1.50) (0.69) (0.55) (0.21)
Book value (32.81) (37.32) 11.34 2.55 5.83 4.06 2.87 4.41 4.03 4.13
Shares, m 3 3 8 25 29 33 34 38 41 43
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 1.45 1.45 3.00 7.89 11.84 8.17 4.28 5.77 3.48 4.22
P/B 0.00 0.00 1.84 8.43 5.13 5.48 4.63 4.73 3.48 4.77
EV/Sales 2.09 2.09 1.64 7.11 9.82 6.94 3.71 4.84 2.80 3.66
EV/FCF (8.20) (8.20) (5.89) (14.05) (21.69) (13.62) (7.72) (25.36) (20.43) (81.02)
Cash, $m
Cash, $m Operating cash flow (17) (18) (15) (32) (31) (40) (42) (19) (12) (1)
Capex 0 0 (1) (2) (3) (6) (10) (8) (10) (8)
Free cash flow (17) (18) (15) (34) (33) (46) (51) (27) (23) (9)
Balance, $m
Balance, $m Working capital 23 26 127 93 205 159 116 188 181 191
Total debt 29 39 39 39 39 35 35 36 35 36
Net debt 1 16 (83) (53) (157) (112) (62) (130) (115) (112)
Shareholders’ equity (109) (129) 90 63 169 134 98 169 167 178
Returns, %
Returns, % ROA (54.71) (61.22) (20.02) (30.06) (25.69) (27.35) (35.20) (22.34) (13.42) (8.06)
ROIC 0.00 0.00 (107.88) (215.31) (194.61) (144.08) (102.96) (74.41) (42.06) (21.38)
ROE 17.29 19.35 89.08 (50.13) (37.61) (37.25) (52.64) (32.38) (18.38) (10.97)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

SiBone vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
IART Integra LifeSciences Holdings Corporation $1.1B — (loss-making) 26.1× +0.76% (above 0%: growing) n/m +193.48% (above 0%: growing) 52.47% 4.61% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.0B — (loss-making) 14.2× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
PRCT PROCEPT BioRobotics Corporation $1.0B — (loss-making) — (loss-making) +19.34% (above 0%: growing) n/m −24.43% (below 0%: shrinking) 66.01% (28.98%) Compare
QDEL QuidelOrtho Corporation $953.9M — (loss-making) — (loss-making) +2.77% (above 0%: growing) n/m −61.45% (below 0%: shrinking) 43.26% (3.46%) Compare
BBNX Beta Bionics, Inc. $933.8M — (loss-making) — (loss-making) +37.76% (above 0%: growing) n/m −1.87% (below 0%: shrinking) 59.04% (79.90%) Compare
SIBN SiBone $892.3M — (loss-making) — (loss-making) +15.18% (above 0%: growing) n/m +60.12% (above 0%: growing) 79.54% (8.58%)
AHCO AdaptHealth Corp. $871.2M — (loss-making) 13.2× +12.66% (above 0%: growing) n/m −128.56% (below 0%: shrinking) 14.08% (18.61%) Compare
INMD InMode Ltd. $824.0M 11.3× 11.8× −0.01% (below 0%: shrinking) −30.95% (below 0%: shrinking) −12.63% (below 0%: shrinking) 74.82% 12.82% Compare
VREX VAREX IMAGING $784.3M 34.7× 43.4× +3.69% (above 0%: growing) n/m +757.14% (above 0%: growing) 36.44% 10.83% Compare
Median of peers $943.8M — 14.2× +5.76% — −7.25% 47.87% 0.58%

All 149 Medical Devices stocks →

SiBone (SIBN) key facts

  • Concern: SiBone reported a net loss of $18.9 million, or a loss of $0.44 per share, for fiscal 2025.
  • Strength: SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024.
  • SiBone (SIBN) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SIBN traded at $19.68, a market capitalization of $892.3 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.1× sales.
  • Return on equity was −11.0% and debt-to-equity 0.20.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 7.18 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

SiBone (SIBN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SIBN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com